---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-035223"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:12:50.142005+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aquestive Q2 revenue up 52% to $20.1M; narrows net loss; raises FY guidance

## Summary
- Total revenue $20.1M vs $13.2M YoY; net loss $2.7M ($0.03/sh) improves from $5.8M loss.
- Non-GAAP adjusted EBITDA positive $1.8M vs -$3.3M; cash $89.9M.
- Raises FY24 revenue guidance to $57-60M (prev. $48-51M); adj. EBITDA loss guidance narrowed to $20-23M.
- Anaphylm NDA submission on track for Q1 2025; launch expected end 2025/early 2026.
- Libervant expanded to ages 2-5; national retail distribution expected Q4 2024; epinephrine prodrug investor day planned.

## SEC filing metadata
- accession: 0001628280-24-035223
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000162828024035223/0001628280-24-035223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000162828024035223/aqst-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-035223
- JSON: https://secwatch.observer/filing/0001628280-24-035223.json
- Plain text: https://secwatch.observer/filing/0001628280-24-035223.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.